The seventh annual BioPharm
America™ international life science partnering conference will be
held September 22-24 at Boston Marriott Copley Place in the
center of Boston's historic Back Bay. The event is a big draw for pharma
and investors who want to access innovative new potential therapies and
cures brought by international biotech companies.
Life science partnering is main topic at BioPharm America™ 2014 (Photo: Business Wire)
"Today is a great time for venture capital investments in innovative
technologies that are tackling big, unmet problems in healthcare," said
Brian Gallagher, Partner at SR One. "Many recent exits and new
funds raised are increasing the appetite for investments in exciting new
biotech startups, which I'm sure will result in a strong investor
turnout at BioPharm America this year."
The investment climate is excellent in 2014, and venture capital
attendance at BioPharm America will be stronger than ever. Investors
already confirmed to attend include: Philip Astley-Sparke, Venture
Partner at Forbion Capital Partners; Peter Barrett, Partner, Atlas
Venture; Cedric Bisson, Venture Partner at Teralys Capital;
Bruce Booth, Partner at Atlas Venture; Bernard Davitian, VP and
Managing Director at Sanofi-Genzyme BioVentures, Sanofi; Todd
Foley, Managing Director at MPM Capital; Brian Gallagher, Partner
at SR One; Jim Geraghty, Entrepreneur-in-Residence at Third
Rock Ventures; Frederick Jones, Director at Broadview Ventures,
Inc.; Nilesh Kumar, Director at MS Ventures; Dan Liu, Senior
Associate at Mitsui Global Investment; Ed Mathers, Partner at New
Enterprise Associates; Takahiro Mukohira, President at MP
Healthcare Venture Management; Liam Ratcliffe, Managing Director at New
Leaf Venture Partners; Kevin Starr, Partner at Third Rock Ventures;
and Robert Weisskoff, Partner at Fidelity Biosciences.
"2014 has been a productive year for biotech, with some significant
regulatory approvals and biotech IPOs performing pretty well. We are
seeing many interesting and potentially groundbreaking scientific
developments," said Frederick Jones, Director at Broadview Ventures,
Inc., a philanthropic venture fund focused on early stage companies
with highly innovative cardiovascular and neurovascular technologies.
"The remainder of 2014 still holds a lot of potential for some
interesting alliances. It's going to make BioPharm America an exciting
place to be this year."
Presenting companies at BioPharm America represent some of the most
innovative companies ranging from early stage projects and small
entrepreneurial companies, to established biotech companies. The 2014
list includes Acetylon Pharmaceuticals, Inc.; AnaptysBio, Inc.; Apitope;
Avexxin AS; Cerecor Inc.; Cerulean Pharma Inc.; Charleston Laboratories,
Inc.; Dicerna; Gene Signal; Igenica Biotherapeutics; Poxel SA; RedHill
Biopharma; Rexahn Pharmaceuticals; RXi Pharmaceuticals; Selvita S.A.;
uniQure; and Vaccinex, Inc, among many more.
More than 900 delegates representing 550 companies from 35 countries
participated in BioPharm America 2013. Delegates in 2013 engaged in
2,950 one-to-one partnering meetings and identified 757 potential
BioPharm America is produced by EBD Group in collaboration with the
Massachusetts Biotechnology Council (MassBio) to facilitate strategic
collaborations with leading companies. One-to-one networking at BioPharm
America™ is powered by partneringONE®, the leading conference
networking solution for the life sciences.
now to attend the largest dedicated partnering event in the eastern
US. Partnering is already open.
About BioPharm America 2014
America™ is where biotech industry partnerships get started. Meet
face-to-face with biotech and pharma executives from around the world to
identify and enter strategic relationships. Equipped with
partneringONE®, BioPharm America is the only event in North America
based on the same reputable formula as EBD Group's acclaimed European
events BIO-Europe® and BIO-Europe Spring®.
Additional links and information:
Follow BioPharm America 2014 on Twitter: @EBDGroup
Or join the Life
Science Partnering group on partnering360® to kick off your
partnering activities before BioPharm America, and throughout the year.
partnering360 is a dynamic network of life science industry experts that
will enable you to continue the dialogue from your partneringONE
meetings at events and identify and connect with new partners anytime,
year-round. Join the vibrant community of life science companies on
Notes to Editors:
Entry to BioPharm America 2014 is free to members of the press,
including full access to the partnering system, sessions, press
conferences, workshops, and pre-arranged partnering meetings. Visit the
BioPharm America conference website at http://www.ebdgroup.com/bpa/registration/press_reg.php
for press registration details.
Press Kit service for BioPharm America™ 2014 is available to enhance
your public relations efforts.
About EBD Group
EBD Group is the leading partnering firm for the global life science
industry. Since 1993, biotech, pharma and medical device companies have
leveraged EBD Group's partnering conferences, technology and services to
identify business opportunities and develop strategic relationships
essential to their success.
EBD Group's conferences are run with the support of leading corporations
and international trade associations and include:
EBD Group's sophisticated web-based partnering service, partneringONE®,
is used as the partnering engine at numerous third-party events around
the world, and partnering360® is the open
online community of life science dealmakers that enhances partnering
experiences throughout the year.
EBD Group is an Informa company. Informa is the largest publicly-owned
organizer of exhibitions, conferences and training in the world.
EBD Group has offices in the USA and Europe.
For more information, please visit www.ebdgroup.com.
MassBio, a not-for-profit organization that represents and provides
services and support for the Massachusetts biotechnology industry, is
the nation's oldest biotechnology trade association. Founded in 1985,
MassBio is committed to advancing the development of critical new
science, technology and medicines that benefit people worldwide.
Representing over 600 biotechnology companies, academic institutions,
research hospitals, and service organizations involved in life sciences
and health care, MassBio works to advance policy and promote education,
while providing member programs and events, industry information, and
Photos/Multimedia Gallery Available: http://www.businesswire.com/multimedia/home/20140819005973/en/
[ Back To NFVZone's Homepage ]